secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001493152-24-042511
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mira Pharmaceuticals' Ketamir-2 shows 60% greater efficacy than gabapentin in preclinical neuropathy study
--------------------------------------------------------------------------------

- Ketamir-2 demonstrated 60% greater efficacy than FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain.
- Company plans additional preclinical studies targeting diabetic neuropathy and PTSD.
- Exploring government funding opportunities to support the development program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224042511/0001493152-24-042511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224042511/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer